经颅骨骨髓途径递送脑细胞保护剂的研究与展望OA
Research and Perspectives on Brain Cytoprotective Agents Delivery via the Skull Bone Marrow Pathway
血脑屏障在阻挡外周致病微生物入颅的同时,亦阻碍大分子、多肽类等药物进入中枢神经系统.目前常用的脑细胞保护剂,如自由基清除剂、钙离子拮抗剂、抗炎调节剂等,虽在卒中临床前实验中展现出明确的脑细胞保护作用,但多由于难以有效跨越血脑屏障等原因,在实际临床转化中疗效不佳.经颅骨骨髓-硬脑膜-类淋巴系统实现脑内药物递送这一新型给药途径,有望绕过血脑屏障,为脑细胞保护剂高效入脑提供新思路.近年来,多项基础实验与临床研究逐步证实,经颅骨骨髓给药在治疗卒中、脑外伤等方面具有良好的可行性、安全性与有效性.此外,颅骨骨髓还具有重要的免疫监视作用,基于此,该途径有望结合纳米载药系统、免疫细胞载药等多模式递送方式,实现精准、高效的脑内药物递送.本文系统梳理了经颅骨骨髓途径递送脑细胞保护剂的相关研究进展,重点介绍了经颅骨骨髓载药转运的新型递送方式,阐明了其绕过血脑屏障、快速靶向脑损伤区域、提高局部药物浓度的独特优势.
The blood-brain barrier(BBB)prevents peripheral pathogenic microorganisms from entering the brain,yet simultaneously blocks macromolecular and polypeptide drugs from reaching the central nervous system.Commonly used brain cytoprotective agents,such as free radical scavengers,calcium antagonists,and anti-inflammatory modulators,have demonstrated clear brain cytoprotective effects in preclinical stroke studies,yet their clinical translation has often been disappointing owing to insufficient BBB penetration.The novel drug delivery route via the skull bone marrow-cerebral dura mater-glymphatic system for intracerebral drug delivery holds promise for bypassing the BBB,offering a novel strategy for efficient brain delivery of brain cytoprotective agents.In recent years,multiple preclinical and clinical studies have progressively demonstrated that skull bone marrow administration has good feasibility,safety,and efficacy in the treatment of stroke,traumatic brain injury,and other conditions.Moreover,given the important immune surveillance function of the skull bone marrow,this route holds promise for combining multimodal delivery strategies,such as nano-drug delivery systems and immune cell-based drug delivery,to achieve precise and efficient intracerebral drug delivery.This review systematically summarizes recent advances in the delivery of brain cytoprotective agents via the skull bone marrow route,with a focus on the novel delivery mode of drug transport via this approach.It highlights the unique advantages of this route in bypassing the BBB,rapidly targeting cerebral lesions,and enhancing local drug concentration.
陈壮壮;徐柳;王楠星;张眉扬;姬若冰;杨沫;刘向荣;王伊龙
北京 100070 首都医科大学附属北京天坛医院神经病学中心北京 100070 首都医科大学附属北京天坛医院神经病学中心北京 100070 首都医科大学附属北京天坛医院神经病学中心北京 100070 首都医科大学附属北京天坛医院神经病学中心北京 100070 首都医科大学附属北京天坛医院神经病学中心北京 100070 首都医科大学附属北京天坛医院神经病学中心北京 100070 神经系统疾病国家临床医学研究中心北京 100070 首都医科大学附属北京天坛医院神经病学中心||北京 100070 神经系统疾病国家临床医学研究中心||北京 100070 国家神经疾病医学中心||北京 100069 首都医科大学人脑保护高精尖创新中心||北京 102206 北京脑科学与类脑研究所
医药卫生
脑细胞保护剂颅骨骨髓类淋巴系统中枢神经系统药物递送
Brain cytoprotective agentSkull bone marrowGlymphatic systemCentral nervous system drug delivery
《中国卒中杂志》 2026 (5)
553-560,8
国家自然科学基金委员会杰出青年科学基金项目(82425101)新基石科学基金会(NCI202531)北京市科技计划项目(Z231100004823036)
评论